A COST-EFFECTIVENESS ANALYSIS OF TACROLIMUS XL IN COMPARISON TO GENERIC TACROLIMUS FROM THE PUBLIC HEALTHCARE SECTOR IN MEXICO

被引：0
|
作者：
Anaya, P. [1 ]
de Anda, J. A. [1 ,2 ]
Salazar, A. [2 ]
Braun, S. [3 ]
机构：
[1] IMS Hlth, Mexico City, DF, Mexico
[2] IMS Hlth, Mexico City, Mexico
[3] Astellas Pharma US Inc, Northbrook, IL USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2727
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK6
引用
收藏
页码：A896 / A896
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico
    Arreola Ornelas, Hector
    Rosado Buzzo, Alfonso
    Garcia, Lourdes
    Dorantes Aguilar, Javier
    Contreras Hernandez, Iris
    Mould Quevedo, Joaquin F.
    [J]. REUMATOLOGIA CLINICA, 2012, 8 (03): : 120 - 127
  • [32] Cost-effectiveness of clopidogrel in Mexico: A long term analysis
    Jerjes-Sanchez, C.
    Trujillo, A.
    Ramos, M. A.
    Hernandez, I
    Alvarado, R.
    Cruz, A.
    Rangel, F. J.
    Morales, E.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A345 - A345
  • [33] Taking stock of cost-effectiveness analysis of healthcare in China
    Butt, Thomas
    Liu, Gordon G.
    Kim, David D.
    Neumann, Peter J.
    [J]. BMJ GLOBAL HEALTH, 2019, 4 (03):
  • [34] Cost-Effectiveness of Vildagliptin Compared to Generic Sulphonylureas Added on to Metformin from a Portuguese Healthcare System Perspective
    Calado, Frederico J.
    Gruenberger, Jean-Bernard
    De Nigris, Enrico
    Silva-Nunes, Jose
    Carvalho, Davide
    [J]. DIABETES, 2012, 61 : A309 - A309
  • [35] Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brazil: Primary Prevention Analysis in the Public Sector
    Ribeiro, Rodrigo Antonini
    Stella, Steffan Frosi
    Camey, Suzi Alves
    Zimerman, Leandro Ioschpe
    Pimentel, Mauricio
    Rohde, Luis Eduardo
    Polanczyk, Carisi Anne
    [J]. VALUE IN HEALTH, 2010, 13 (02) : 160 - 168
  • [36] FROM PRINCIPLE TO PUBLIC-POLICY - USING COST-EFFECTIVENESS ANALYSIS
    NEUMANN, PJ
    [J]. HEALTH AFFAIRS, 1994, 13 (03) : 206 - 214
  • [37] Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges
    Espinosa, Oscar
    Rodriguez-Lesmes, Paul
    Romano, Giancarlo
    Orozco, Esteban
    Basto, Sergio
    Avila, Diego
    Mesa, Lorena
    Enriquez, Hernan
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024,
  • [38] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Holanda, P.
    Salgado De Santana, C.
    Senna, T.
    Carmo, L.
    Alexandre, R. F.
    [J]. VALUE IN HEALTH, 2021, 24 : S96 - S96
  • [39] COST-EFFECTIVENESS OF EVEROLIMUS PLUS REDUCED TACROLIMUS IN DE NOVO LIVER-RECIPIENTS IN THE ITALIAN SETTING
    Bianic, F.
    Campbell, R.
    De Simone, P.
    Roccia, A.
    Gregson, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A367 - A367
  • [40] Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting
    Bianic, Florence
    Campbell, Rosanne
    Damera, Vidya
    De Simone, Paolo
    Roccia, Alessandro
    Gregson, Jill
    Ricci, Jean-Francois
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (09) : 866 - 873
12345